Arthrosi, a company invested in and incubated by Viva Biotech, has reached an acquisition deal with Sobi worth up to US$1.5 billion.

Acquisition Announcement: Swedish Orphan Biovitrum AB (Sobi) has entered into an acquisition agreement with Arthrosi Therapeutics for up to US$1.5 billion, including an upfront payment of US$950 million and contingent consideration of up to US$550 million, expected to close in the first half of 2026.

Strengthening Gout Pipeline: The acquisition enhances Sobi's gout treatment portfolio by adding pozdeutinurad, a next-generation URAT1 inhibitor currently in Phase 3 clinical studies, aimed at improving management for patients with progressive and tophaceous gout.

Viva Biotech's Role: Viva Biotech, which invested in and incubated Arthrosi, anticipates a gain of approximately US$40 million from the acquisition, contingent on regulatory and performance milestones, and plans to continue collaboration with Arthrosi for active pharmaceutical ingredient supply.

Leadership Statements: Sobi's CEO emphasized the acquisition's potential to accelerate growth and improve treatment options for gout patients, while Arthrosi's CEO expressed excitement about the partnership, highlighting Sobi's expertise in commercialization to advance pozdeutinurad.